Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and Capecitabine in Recurrent/Metastatic SCCHN and NPC
NCT01267240Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2010
- Primary completion
- Jun 2015
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of vorinostat in squamous cell carcinoma of the head and neck (HNSCC), nasopharyngeal carcinoma (NPC), sponsored by National Cancer Institute. Started Dec 2010; status: terminated.
02
Drugs
vorinostat
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT01267240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01267240.